Narrative review—how to access nodules: role of new technology including navi- and robo-bronchoscopy

Alexander Gregor^, Tsukasa Ishiwata^, Terunaga Inage^, Kazuhiro Yasufuku^  

Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada  

Contribution: (I) Conception and design: All authors; (II) Administrative support: K Yasufuku; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.  

Correspondence to: Kazuhiro Yasufuku, MD, PhD, FRCSC. 200 Elizabeth St, EN 9N-957, Toronto, Ontario, M5G 2C4, Canada.  
Email: kazuhiro.yasufuku@uhn.ca.  

Abstract: Implementation of lung cancer screening is expected to increase the detection of lung nodules, many of which will require intervention for diagnosis or management. Transbronchial approaches have generally shown a favourable risk profile relative to transthoracic techniques. Bronchoscopic interventions are therefore particularly attractive in comorbid and frail patient populations. Fundamental to any biopsy or local therapy is accurate device delivery. However, transbronchial techniques must work within the constraints of bronchial anatomy, which may not inherently lend itself to easy access of suspicious nodules. A variety of technologies have been developed to improve the clinicians’ ability to reliably access nodules via a transbronchial approach. The MEDLINE database was searched from 2000 through June 2020 on the topic of navigation bronchoscopy and associated technologies. This article will review several technology classes, including intraoperative imaging that provides real-time anatomic information (computed tomography fluoroscopy, cone-beam computed tomography, augmented fluoroscopy), navigation systems that facilitate planning/selection of bronchial tree pathways [virtual bronchoscopic navigation (VBN), electromagnetic navigation bronchoscopy (ENB)], evolutions in bronchoscope design that improve function within the peripheral lung [ultrathin bronchoscopy (UTB), robotic bronchoscopy], and new platforms that permit access beyond the bronchial wall (bronchoscopic transparenchymal nodule access, transbronchial access tool). Familiarity with the strengths and limitations of these technologies are critical for their effective use.  

Keywords: Navigation bronchoscopy; lung nodule; robotic bronchoscopy  

Received: 24 June 2020; Accepted: 19 February 2021.  
doi: 10.21037/ccts-20-122  
View this article at: http://dx.doi.org/10.21037/ccts-20-122  

Introduction  

Results of the National Lung Screening Trial (NLST) and Dutch-Belgian lung-cancer screening trial (NELSON) demonstrated reduced lung cancer mortality with implementation of computed tomography (CT)-based screening (1,2). This was achieved at least in part through a shift towards early stage diagnosis (1,2). However, most positive scans were in fact false positives, and although there are several strategies for risk-stratifying pulmonary nodules, tissue diagnosis remains critical (1,2). The population has at the same time become older and more comorbid, altering the risk-benefit calculation when considering standard
approaches for biopsy, localization, and therapy (3). CT-guided transthoracic biopsy, the current gold-standard, has a pooled diagnostic yield of 93% but a pneumothorax rate of 26% (4). Surgery may not be feasible due to comorbidities or patient preference.

Transbronchial approaches have generally shown a lower complication rate than transthoracic approaches, with a pneumothorax rate as low as 1.5% (5). This has made it an appealing alternative approach for biopsy, localization, and therapy. In the context of biopsy, conventional bronchoscopy is generally effective for central lesions (88% sensitivity) (6). However, this falls precipitously for peripheral lesions (34% and 66% sensitivity for <2 and >2 cm diameter lesions, respectively) (6). This diagnostic performance portends poorly for other transbronchial procedures; accurate delivery of biopsy forceps relies on the same principles as any other instrument. In this context, diagnostic yield can function as an effective surrogate for nodule access, though they are not necessarily equivalent. Nodule access (i.e., the ability to bring a bronchoscope or instrument into the region of a target) is necessary, but not sufficient, for successful biopsy. We direct readers to Dr. Tsukada’s review in this issue for a more detailed discussion on considerations for transbronchial biopsy, including endobronchial ultrasound (EBUS) (7).

To address the challenge of nodule access, a variety of new technologies have been developed (Table 1). These technologies are frequently complementary, and many studies often evaluate several of them simultaneously. It is critical that bronchoscopists be familiar with the strengths and limitations of these individual components to develop a flexible and effective nodule access strategy. For this review, we searched the MEDLINE database for human clinical studies published in English from 2000 to June 2020 and present the following article in accordance with the Narrative Review reporting checklist (available at http://dx.doi.org/10.21037/ccts-20-122).

### Intraoperative imaging

Conventional two-dimensional (2D) fluoroscopy has two limitations. First, nodules may not be fluoroscopically visible.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Overview</th>
<th>Example commercial system (manufacturer)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intraoperative imaging</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Computed tomography fluoroscopy</td>
<td>Intraoperative cross-sectional images albeit narrow field-of-view</td>
<td></td>
</tr>
<tr>
<td>Cone-beam computed tomography</td>
<td>Intraoperative cross-sectional images, fluoroscopy-capable</td>
<td></td>
</tr>
<tr>
<td>Augmented fluoroscopy</td>
<td>Overlay of navigation data onto intraoperative fluoroscopic image</td>
<td>LungVision (Body Vision)</td>
</tr>
<tr>
<td><strong>Navigation systems</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virtual bronchoscopic navigation</td>
<td>Reconstruction of CT data to simulate endoscopic view/path</td>
<td>Bf-NAVI/DirectPath (Olympus), LungPoint (Broncus)</td>
</tr>
<tr>
<td>Electromagnetic navigation</td>
<td>Real-time tracking of instrument in three-dimensional space</td>
<td>superDimension (Medtronic), SPiN System (Veran)</td>
</tr>
<tr>
<td>Bronchoscopy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrathin bronchoscopy</td>
<td>Small diameter, highly maneuverable bronchoscope</td>
<td>MP-190F/290F (Olympus)</td>
</tr>
<tr>
<td>Robotic bronchoscopy</td>
<td>Highly maneuverable, stable platform with integrated navigation</td>
<td>Monarch (Auris), Ion (Intuitive)</td>
</tr>
<tr>
<td>Transparenchymal access</td>
<td>Puncture-and-dilating kit to access nodules beyond the bronchial tree</td>
<td>Archimedes (Broncus), CrossCountry (Medtronic)</td>
</tr>
</tbody>
</table>
visible. Second, fluoroscopy may be falsely reassuring if the bronchoscope/instrument is overlapping the target in a plane perpendicular to the fluoroscopic view (8). Advanced intraoperative imaging can facilitate nodule access by confirming instrument position relative to the nodule and, if positioning is inaccurate, informing selection of an alternate route.

**Computed tomography fluoroscopy**

Modern multidetector CT scanners can be employed for CT fluoroscopy. By positioning the patient such that the target nodule is centered within the scanner bore, the scanner can be intermittently activated to rapidly acquire real-time intraoperative cross-sectional images (9). This technique has the greatest utility for small lesions, which are likely fluoroscopically invisible. A retrospective study comparing multidetector CT fluoroscopy (n=82) with 2D fluoroscopy (n=78) found the diagnostic yield was significantly greater for small lesions (42.9% versus 7.7% in lesions <10 mm, 54.2% versus 20% in lesions 11–15 mm), but unchanged for larger lesions (10). Although a later randomized trial found no advantage for CT fluoroscopy, this study did not stratify by nodule size and the lesions were relatively large in both groups (mean 46 and 37 mm, respectively) (11).

**Cone-beam computed tomography**

Cone-beam CT (CBCT) generates cross-sectional images through rotation of a C-arm, which can be more easily adjusted and worked around during normal procedures. These systems have formed key part of so-called ‘hybrid operating rooms’ that integrate advanced imaging systems in procedure areas (12). A pilot study reported on 20 patients who underwent CBCT after failed transbronchial biopsy with conventional fluoroscopy and radial probe endobronchial ultrasound (RP-EBUS) (13). Addition of CBCT improved navigation success (i.e., visualization by RP-EBUS) from 50% to 75% (P=0.02), and diagnostic yield from 50% to 70% (P=0.04) (13).

**Augmented fluoroscopy**

Augmented fluoroscopy is the enhancement of standard 2D fluoroscopic images through the overlay of additional data, such as segmentation data from a corresponding CT scan. As CBCT can acquire both cross-sectional and 2D fluoroscopic images, CBCT segmentation data (e.g., nodule) can be overlaid onto the 2D fluoroscopic image, provided the patient is not moved (14). The augmentation data automatically compensates for changes in C-arm position (15). Pritchett et al. evaluated this technique in conjunction with electromagnetic navigation bronchoscopy (ENB) in 75 patients (15). Although lesions were small (median 16 mm) and often fluoroscopically invisible (49%), the overall diagnostic yield was 83.7% (15). This compares favourably with ENB experience (see section ENB). However, the average number of CBCT scans per patient was 1.5, making the value of augmented fluoroscopy alone unclear (15).

A potential upcoming platform is LungVision (Body Vision Medical Ltd., Israel), an FDA-approved system that can register preoperative CT data to standard intraoperative fluoroscopy using fluoroscopic tomosynthesis, a radiopaque bead-filled registration board, and artificial intelligence (16). Included software can generate a navigation plan that is overlaid onto the real-time fluoroscopy (17). A multicentre trial of 200 patients (average nodule size 17 mm) was described in an abstract, reporting 86% navigation success (CBCT or RP-EBUS confirmation) and 78% diagnostic yield (17). Formal publication of the trial results is pending.

**Navigation systems**

As intraoperative imaging becomes more advanced (see section Augmented fluoroscopy), the distinction between imaging and navigation systems becomes somewhat arbitrary. At their core, navigation systems process preoperative CT images to generate a navigation route to a target. However, unlike augmented fluoroscopy, which collapses three-dimensional (3D) information into a 2D projection, navigation systems generally retain and display 3D information throughout the procedure.

**Computed tomography-body divergence**

The registration of high-quality preoperative images is foundational to all navigation systems. However, the lag between scan acquisition and bronchoscopy can lead to discrepancy between CT and ‘current’ patient anatomy, referred to as CT-body divergence. The first challenge is practical: the procedure may no longer be necessary. One study found same-day CT scan resulted in cancellation of approximately 7% of procedures due to nodule regression (18).
The second challenge is nodule displacement from breathing. A retrospective study comparing inspiratory and expiratory phase CT scans in 46 patients found nodule displacement was on average 17.6 mm, but varied from 10.6 mm in the left upper lobe to 25.3 mm in the right lower lobe (19). The displacement vector was also complex, occurring primarily along the anteroposterior and craniocaudal planes (19). A third challenge is nodule displacement by bronchoscope wedging. A study in pigs with positional sensors placed in the bronchial tree found that although bronchoscope movement in the central airways caused minimal disruption, wedging the bronchoscope in a target segment displaced the associated sensor on average by 8.2 mm (20). A final challenge is that intraoperative changes, such as atelectasis, may alter nodule position. CT-body divergence establishes a clear role for complementary real-time imaging (e.g., RP-EBUS, CT, fluoroscopy) during navigation bronchoscopy.

**Virtual bronchoscopic navigation (VBN)**

VBN is the 3D reconstruction of the airways from CT data to simulate the expected endoscopic view (21). Images of the virtual lumen can then be directly compared with findings during bronchoscopy. VBN can be used for simulation (i.e., preoperative rehearsal) or navigation (i.e., intraoperative cross-reference with bronchoscopy). The two approaches were compared in a retrospective study using ultrathin bronchoscopy (UTB) and CT fluoroscopy (22). Diagnostic sensitivities were similar (63% versus 70%, \( P=0.48 \)), but simulation was associated with longer time to first biopsy (13 versus 8.5 min, \( P<0.05 \)) and longer total exam time (29.3 versus 24.5 min, \( P<0.05 \)) (22). Most contemporary uses of VBN employ the navigation approach.

As VBN is a form of CT reconstruction, it is feasible to perform VBN with generic CT workstation software, though more manual work is generally required (23-25). The bulk of VBN data focuses on two systems purpose-built for VBN: DirectPath/Bf-NAVI (Olympus Corporation, Japan) and LungPoint (Broncus Medical Inc., USA). These systems have advanced planning features, such as assisted target segmentation and automated path generation, and user interfaces better designed for intraoperative use. DirectPath/Bf-NAVI includes a viewer that displays the virtual lumen and highlighted navigation route; however, the reconstruction must be manually advanced/withdrawn/rotated as the procedure progresses (26). LungPoint includes image recognition capabilities for automatic alignment of VBN images with the bronchoscopic view (27).

When synchronized, target position and the navigation route can be overlaid onto the endoscopic video (27).

VBN is often combined with other modalities. Several trials support that VBN allows faster navigation to nodules when combined with RP-EBUS. However, the benefit for navigation success or diagnostic yield is less clear. Oshige et al. prospectively compared transbronchial nodule biopsy using RP-EBUS plus guide sheath (GS) with (n=57) or without (n=55) Bf-NAVI (28). Diagnostic yield was not significantly different (84.2% versus 80%), but time to first biopsy was shorter with VBN (5.5 versus 9.3 min, \( P=0.0004 \)) (28). Bo et al. randomized 1,010 patients to unassisted transbronchial biopsy, RP-EBUS/GS-assisted biopsy, or RP-EBUS/GS plus VBN-assisted biopsy for nodules 8–30 mm in diameter (29). Diagnostic yield was lowest without guidance (41.2%, \( P<0.01 \)), but no advantage was seen adding VBN to RP-EBUS/GS (74.3% and 72.3%, respectively), regardless of nodule size (29). RP-EBUS localization rates did not improve with VBN, although the time to localize was shorter (7.96 versus 11.92 min, \( P<0.01 \)) (29).

If VBN is to have any benefit on nodule access, it is most likely for small nodules. Ishida et al. randomized 199 patients with nodules ≤30 mm to Bf-NAVI-assisted or unassisted transbronchial biopsy; a thin bronchoscope (4.0 mm outer diameter) and RP-EBUS were used in both groups (30). Diagnostic yield was significantly improved with VBN (80.4% versus 67%, \( P=0.032 \)), which appeared to be driven by nodules <20 mm (75.9% versus 59.3% for \( <20 \) mm, \( P=0.056 \); 87.8% versus 80.6% for 20–30 mm, \( P=0.382 \)) (30). RP-EBUS visualization improved with VBN (92.9% versus 81.1%, \( P=0.014 \)) (30). Time to first biopsy was reduced (8.1 versus 9.8 min, \( P=0.045 \)) (30). Xu et al. randomized 115 patients to DirectPath-assisted or unassisted transbronchial biopsy using RP-EBUS, and found on subgroup analysis that VBN improved diagnostic yield in nodules ≤20 mm (80% versus 53.6%, \( P=0.041 \)) (31). Time to RP-EBUS localization was shorter with VBN (5.7 versus 8.6 min, \( P=0.015 \)) (31).

Studies without RP-EBUS do not unmask additional VBN advantages. Asano et al. randomized 334 patients with nodules ≤30 mm to Bf-NAVI-assisted or unassisted transbronchial biopsy using UTB (2.8 mm outer diameter) (32). There was no significant difference in diagnostic yield (67.1% versus 59.9%, \( P=0.173 \)), although a benefit was seen for peripheral lesions (64.7% versus 52.1%, \( P=0.047 \)) (32). Time to first biopsy was shorter with VBN, although the effect size was smaller than in other studies (6.4 versus 6.8 min, \( P=0.021 \)) (32). A similar matched case-control study compared unguided UTB (n=110)
with LungPoint-assisted UTB (n=55) (33). Diagnostic yield was not significantly improved with VBN (47% versus 40%, P=0.354), though a trend to significance was noted for nodules ≤20 mm (42% versus 24%, P=0.069) (33).

An interesting question is whether VBN, which is reconstructed preoperative cross-sectional imaging, has any value over real-time cross-sectional imaging. Kato et al. prospectively compared 100 patients undergoing transbronchial CT fluoroscopy-guided biopsy with or without LungPoint-assistance (34). All nodules were ≤20 mm, peripheral, and had a bronchus sign (34). Surprisingly, diagnostic yield was higher with LungPoint (84% versus 58%, P=0.013) (34). One possible explanation is that more biopsies were taken with VBN (3.54 versus 2.98, P=0.01), given the shortened time to first biopsy (15 versus 19 min, P=0.008) (34). However, it is also likely that interpretation of VBN is more intuitive than interpretation of axial CT imaging.

In summary, VBN's most consistent benefit is reduced time-to-target, providing more time for the procedure proper (e.g., biopsy). Although data is less consistent, VBN likely has benefit for small peripheral nodules, whose access route may be more difficult to plan without assistance. Leveraging this advantage requires use of technologies suitable for peripheral access (e.g., RP-EBUS, UTB). An advantage of VBN is its accessibility. Once installed there is no per-procedure cost, and interpretation of the navigation guidance is intuitive. An obvious limitation is the reliance on the endoscopic view; the utility of VBN diminishes if the endoscopic view is obscured (e.g., bleeding, mucus plugging) or if the bronchoscope cannot be physically advanced along the planned route.

**ENB**

When an electromagnetic sensor moves through an electromagnetic field, changes in voltage can be used to calculate its 3D position within the field; this is the foundation of ENB (35). Broadly, ENB begins like VBN: CT data is imported, the target is selected, and a navigation route is generated. This route can be reviewed manually as a form of VBN. Registration of an electromagnetic sensor (moving within a field around the patient's chest) to an imported scan allows sensor position to be displayed in relation to the patient's anatomy.

There are currently two approved ENB systems, which differ slightly in their workflow. The superDimension (Medtronic, USA) system consists of four key components: the location board, patient sensors, the disposable extended working channel (EWC), and the disposable locatable guide (LG). Planning can be done using any recent high-quality CT chest. The location board is placed under the patient and generates the electromagnetic field. Patient sensors, placed on the chest, allow compensation for patient movement. The LG contains the electromagnetic sensor and fits within the EWC. To register the CT data to the ENB system, the EWC/LG is inserted through the bronchoscope and held at designated targets (e.g., main carina) or, in newer versions, passed through each lobar bronchus for automatic registration. The EWC is angulated, and thus functions as a steerable GS to selectively access bronchial branches along the navigation route. Once the target is reached, the EWC is locked in place and the LG removed to allow use of other instruments.

The SPiN System (Veran Medical Technologies, USA) consists of three key components: the vPads, the field generator, and tracked instruments. A set of inspiratory and expiratory CT scans must be acquired on the procedure day with the vPads (a set of 3 adhesive sensors) already secured on the patient's anterior chest. When the scans are imported into the planning software, markers in the vPads are used for automatic registration (hence the requirement for same-day imaging to reduce registration error). Inspiratory and expiratory scans are used for respiratory gating, with breathing detected by the vPads. During ENB, the field generator is placed directly over the patient and disposable instruments with embedded electromagnetic sensors are used.

Data on ENB performance is influenced on the use of adjunctive technologies, like VBN. Eberhardt and colleagues randomized 118 patients undergoing transbronchial nodule biopsy to RP-EBUS alone, superDimension alone, or superDimension plus RP-EBUS (36). Diagnostic yield was significantly better with the combined approach (88%, P=0.02) compared to RP-EBUS (69%) and ENB (59%) (36). ENB performed significantly worse in the lower lobe (29%, P=0.01), in keeping with CT-body divergence (36). Several groups subsequently evaluated conditional use of ENB. A retrospective study of 60 patients undergoing transbronchial biopsy of 10–60 mm lesions with RP-EBUS found that performing superDimension ENB after failed RP-EBUS visualization improved lesion localization (93% versus 75%, P=0.001) (37). Lesions requiring ENB were generally smaller (22 versus 30 mm, P<0.05), less likely to have a bronchus sign (33% versus 76%, P<0.01), and more likely to be in the upper lobe (P<0.05) (37). However, ENB did not significantly improve diagnostic yield (50% versus 43%, P=0.125) (37). A prospective study of 236 consecutive
patients evaluated use of superDimension ENB after RP-EBUS and ‘VBN’ (i.e., review of superDimension planning data) failure (38). The addition of ENB improved RP-EBUS visualization from 77% to 85.3% (38). However, the improvement in diagnostic yield was marginal (54.7% versus 58.4%) (38). Lesions requiring ENB were again smaller (23.8 versus 19.1 mm, P=0.006) (38).

The inability to replicate the results of the Eberhardt trial may reflect the real-world experience with ENB. A 2014 meta-analysis calculated the pooled diagnostic yield of ENB to be 64.9% (39). On the lower end, a multicentre registry of transbronchial peripheral nodule biopsy reported the diagnostic yield of ENB alone to be 38.5%, improving to 47.1% when coupled with RP-EBUS (40). On the higher end, the NAVIGATE trial, a large multicenter single-cohort study of 1,215 subjects who underwent SuperDimension ENB, reported a diagnostic yield of 72.9% on 1 year follow-up (41). Complete 24-month follow-up data is expected soon and may help clarify realistic expectations on the benefits of ENB.

There have been no head-to-head comparisons between the superDimension and SPiN System. CT-body divergence supports the value of the SPiN System’s respiratory gating; however, a review of diagnostic yields across ENB studies do not reveal any obvious differences (35). Both systems continue to receive software updates that improve their performance and capabilities. For example, a recent update to the superDimension software introduced a feature for correcting CT-body divergence using intraoperative fluoroscopic tomosynthesis (42). A retrospective study comparing standard ENB (n=90) with tomosynthesis-corrected ENB (n=59) found diagnostic yield was significantly improved (54% versus 79%, P=0.0019); the median registration correction was 12.2 mm (42).

Reduced patient movement through general anesthesia may also have benefit in reducing CT-body divergence. One meta-analysis found ENB diagnostic yield with general anesthesia outperformed intravenous sedation (69.2% versus 57.5%, P=0.02) (39). However, there was significant heterogeneity between studies using general anesthesia and those using intravenous sedation. One retrospective study directly comparing general anesthesia (n=62) and intravenous sedation (n=58) found no difference in diagnostic yield (70% versus 78%, P=0.38), but significantly reduced procedure time with intravenous sedation (58 versus 43 min, P=0.0005) (43).

In summary, existing data supports the use of ENB in combination with other modalities, particularly RP-EBUS. Lesions benefiting from ENB are generally smaller (≤20 mm). However, the magnitude of ENB’s benefit remains less clear. Improved RP-EBUS localization success with ENB suggests the system can improve access to the area of the nodule, but this does not necessarily translate to nodule access itself. This distinction may be irrelevant for procedures that do not require precise access, such as preoperative pleural dye marking. Discrepancy between localization and diagnostic yield may be multifactorial, such as shifting EWC position during RP-EBUS exchange, but CT-body divergence likely plays a significant role. Refinement in CT-body divergence mitigation strategies, such as enhanced respiratory gating or tomosynthesis-correction, may improve ENB’s performance over time. A major limitation of ENB is cost, which includes both installation fees and disposable instruments. Thoughtful identification of cases most likely to benefit from ENB are critical to its cost-effective use.

**Bronchoscopy**

**UTB**

The outer diameter cut-off between conventional, thin, and UTB is not clearly defined, although ≤3 mm for UTB and ≥5 mm for conventional bronchoscopy is often quoted (8,44,45). UTB’s smaller outer diameter and increased range of motion improves maneuverability within the peripheral bronchial tree. This has historically come at the cost of reduced working channel size; however, this cost is reduced in newer generation UTB (MP-190F/290F, Olympus, Japan; 3 mm outer diameter, 1.7 mm working channel).

One non-inferiority trial randomized 305 patients with nodules ≤30 mm to UTB or thin bronchoscopy (4 mm outer diameter, 2 mm working channel) (46). All procedures were performed with Bf-NAVI and RP-EBUS; however, the thin bronchoscopy group used a GS (46). The non-inferiority margin (−10% diagnostic yield) was met, with UTB outperforming thin bronchoscopy (75% versus 61%, P=0.008) (46). Subgroup analysis revealed UTB performed better for nodules in the peripheral-third of the lung (P=0.002) and bronchus sign-positive lesions (P=0.001) (46). Consistent with these findings, UTB could reach more peripherally (median 5th versus 4th bronchial generation, P=0.001) (46). A potential criticism of this trial was that both groups used the same biopsy instruments, and thus the thin bronchoscopy group did not fully leverage the larger working channel (e.g., larger forceps, transbronchial needle aspiration). As such, the group conducted a second
randomized trial allocating 356 patients to either UTB or thin bronchoscopy without requiring GS use (47). The advantage of UTB was reaffirmed (70.1% versus 58.7% diagnostic yield, P=0.027) (47).

These trials support use of modern UTB for nodule access, particularly small peripheral nodules. Institutions regularly using VBN and/or RP-EBUS can easily integrate these devices into their current workflows. However, to our knowledge the working channel remains too small for existing ENB systems. This makes the choice between UTB and ENB mutually exclusive, and thus their relative performance will be of interest. Of note, diagnostic yields in both UTB randomized trials were similar to that reported in a large longitudinal ENB trial, NAVIGATE (41).

**Robotic bronchoscopy**

Fundamental features of bronchoscope design can contribute to difficulty accessing peripheral nodules. Transmission of mechanical force from the bronchoscope handle to the tip can be limited by bend or loop formation in the insertion tube. The inability to provide consistent forward force can also contribute to tip slippage during bronchoscope or patient movement, resulting in loss of nodule access. Furthermore, accessing peripheral bronchi can require subtle movements that may be difficult to perform using rotation and flexion-extension alone, particularly if rotation results in compromised endoscopic visualization.

Robotic bronchoscopes aim to address these challenges by offering increased stability and maneuverability. Two platforms have regulatory approval: Monarch (Auris Health Inc., USA) and Ion (Intuitive Surgical Inc., USA) (Figure 1).

Monarch employs a ‘telescoping’ design that embeds an inner 4.4 mm scope (2.1 mm working channel) within a 6.0 mm outer sheath; the bronchoscope is operated using a handheld controller (48). The inner and outer components can be manipulated together or independently (48). ‘Parking’ the outer sheath can provide additional stability as the inner scope is advanced further ahead (49). Navigation is provided through

---

**Figure 1** Robotic bronchoscopy platforms. The two currently available robotic bronchoscopy platforms are the Monarch® from Auris™ Health, Inc. (A) and the Ion™ from Intuitive Surgical®, Inc. (B). The two systems differ in several key aspects. For example, the former is manipulated using a handheld controller (A), while the latter uses an upright console (B). The Monarch® employs a telescoping setup, whereby a larger catheter (light blue) can be parked before advancing a flexible inner section that contains the working channel (dark blue, C). The Ion™, by comparison, uses a single insertion tube design (D). Images ©2020 Auris™ Health, Inc. and Intuitive Surgical®, Inc. Reproduced with permission.
integrated ENB capabilities (50). By comparison, Ion consists of a single 3.5 mm insertion tube with 2.0 mm working channel, operated via a console using a scroll wheel and track ball (51). Embedded within the device is a shape sensing fiber that monitors the scope’s configuration in 3D space; this data can be used for registration with a preoperative CT scan to provide intraoperative navigation (52).

**Monarch (Auris Health)**

Monarch has shown potential performance advantages over flexible bronchoscopy in a series of cadaver studies. Despite its larger outer diameter, Monarch demonstrated improved peripheral reach compared to thin bronchoscopy (4.2 mm outer diameter) in every lung segment of mechanically ventilated cadavers, as measured by increased mean bronchial generation count (range, 1–6) and increased mean insertion depth (range, 35.1–48.4 mm) (49). A follow-up study with randomly placed small peripheral pseudotumors found the diagnostic yield to be 94% when used with RP-EBUS and ENB (48).

The first Monarch clinical experience was reported in 15 patients; RP-EBUS and the system’s ENB capabilities were not used (53). Tissue was obtained in 14 cases without complication (53). A subsequent multicenter study in 165 patients reported 88.6% navigation success and a diagnostic yield of 69.1% to 77% (depending on classification of patients with insufficient follow-up data) when combined with ENB and RP-EBUS (54). The pneumothorax rate was 3.6%, and airway bleeding requiring exchange with a standard bronchoscope for intervention occurred in 2.4% of cases (54).

**Ion (Intuitive Surgical)**

Comparison between UTB/RP-EBUS alone, superDimension alone, and Ion alone was performed in a cadaver model with randomly placed small pseudotumors (51). Participants deployed the biopsy needle when a nodule was localized by RP-EBUS or ENB/Ion navigation, and biopsy needle position was confirmed by CBCT (51). Nodule localization success was 65% with UTB/RP-EBUS, 85% with ENB, and 100% with Ion (51). Successful puncture was significantly greater with Ion (80%) compared to ENB (45%, P=0.022) and UTB/RP-EBUS (25%, P<0.001) (51).

The first clinical report of Ion, in conjunction with RP-EBUS, included 29 patients (52). Nodule access (defined by retrieval of tissue other than normal lung) was 96.6%; diagnostic yield was 79.3% (52). No pneumothorax or airway injury occurred (52).

**Summary**

Experience with robotic bronchoscopy is preliminary but encouraging. Further studies will be required before the cost-effectiveness of a robotic bronchoscopy program, including differences between Monarch and Ion, can be estimated. Notably, all clinical trials have used general anesthesia, which increases the logistical burden of such procedures.

**Transparenchymal access**

Transbronchial techniques are constricted by the bronchial anatomy, with limited access to nodules not immediately adjacent to the bronchial wall. This is reflected by multiple studies demonstrating an association between diagnostic yield and the presence of a bronchus sign on CT or concentric visualization on RP-EBUS (8). Transparenchymal systems integrate navigation technologies and tunneling instruments to access nodules not otherwise amenable for transbronchial approaches.

The Archimedes Virtual Bronchoscopy Navigation System (Broncus Medical Inc., USA), also referred to as bronchoscopic transparenchymal nodule access (BTPNA), employs a LungPoint VBN-like foundation. During planning, the target is marked, and the system identifies a point of entry (POE) along the bronchial wall that provides a direct route without traversing vessels (55). This information is used to generate a final BTPNA-VBN plan for navigating to the POE. BTPNA is performed by puncturing the POE with a coring needle, dilating using a balloon dilator, and then advancing a GS with blunt dissecting stylet (55). Guidance then transitions from VBN to augmented fluoroscopy, displaying a 2D projection of the navigation plan and nodule location (55). Once the target is reached the stylet is removed, and instruments can be placed through the sheath.

CrossCountry (Medtronic, USA), also referred to as the transbronchial access tool (TBAT), employs superDimension ENB. During planning, the target nodule, desired exit point, and danger zones (e.g., vessels) are marked (56). A plan is then generated that can be modified to ensure tunneling through the danger zone is avoided (56). TBAT begins as ENB with navigation to the exit point, at which point the LG is exchanged for a puncture wire (56).
After puncturing the bronchial wall, a Seldinger technique is used (56). A dilator is fed over the wire to tunnel to the nodule (56). Once in position, the EWC is advanced over the dilator, the dilator is removed, and instruments can be passed through the EWC (56).

**Archimedes (bronchoscopic transparenchymal nodule access)**

A BTPNA-and-resect trial was performed in 12 patients, with a diagnostic yield of 83% (55). The two non-diagnostic cases were in the apical left upper lobe (55). BTPNA could not be performed in those cases (55). A subsequent series of BTPNA alone in 6 patients reported procedure success (including diagnostic tissue) in 5 cases; the 1 failed case was due to an error generating the augmented fluoroscopy image (57). Two cases developed a pneumothorax, with one requiring chest drain; both cases had nodules close to the pleura (57).

**CrossCountry (transbronchial access tool)**

The first series of TBAT included 3 patients with nodules inaccessible by conventional ENB (58). CBCT and/or fluoroscopy were used in all cases (58). There were no complications, although one case was non-diagnostic (58). A subsequent series of 12 patients with TBAT and CBCT reported a procedural success rate of 75% with an overall diagnostic yield of 66% (56). One pneumothorax occurred, requiring chest drain (56). Failed TBAT access occurred in areas requiring sharply angled approaches (56).

**Summary**

BTPNA/TBAT are feasible. However, additional safety and performance information is needed. The potential consequences of CT-body divergence on vessel (rather than nodule) position remains to be seen, with the incumbent risks of inadvertent vessel puncture. Updates to VBN and ENB software may simplify the planning process for BTPNA/TBAT. General anesthesia will likely be required, given the risks associated with uncontrolled parenchymal dissection during unexpected movement. BTPNA/TBAT may also have some difficulties in areas of high angulation. Placement of instruments in the EWC reportedly caused unintended straightening that resulted in misalignment with the planned puncture site (56). The tip stability and maneuverability of robotic platforms may ultimately be one strategy to address these challenging regions.

**Conclusions**

A variety of technologies are available to facilitate nodule access. Many, such as VBN, ENB, and UTB, are showing continued maturation and evolution. Others, such as robotic bronchoscopy and transparenchymal access, are in the early phases of their evaluation. A common thread in review of these systems is that their performance is optimized through thoughtful combination with other relevant technologies. Reliance on any single platform alone is unlikely to realize significant benefits for nodule access. Navigation platforms by their nature rely on preoperative imaging and planning procedures prior to use. Patients that may require navigation must therefore be identified before their scheduled bronchoscopy. Like much in medicine, there continues to be a need for large multicentre randomized trials both for nascent (e.g., robotic bronchoscopy) and evolving (e.g., ENB) technologies to understand the cost-effectiveness of these increasingly complex systems.

The literature suggests, as expected, that these technologies offer most benefit for lesions that are poorly accessed by conventional bronchoscopy: small (≤20 mm) nodules in the periphery (outer one-third lung field). Current trends indicate the future of bronchoscopy is smaller, more maneuverable bronchoscopes complemented by navigation systems that can correct for CT-body divergence. However, routine upfront use of advanced technologies in all bronchoscopic procedures is unlikely to be cost-effective. Rather, careful review of the patient’s CT scan, familiarity with RP-EBUS, and availability of fluoroscopy remain invaluables, serving as a foundation upon which additional technologies should be applied.

**Acknowledgments**

The authors would like to thank Judy McConnell (Toronto General Hospital) for her assistance with laboratory management.

**Funding:** KY is supported by the William Coco Chair in Surgical Innovation for Lung Cancer. AG is supported by a Canadian Institutes of Health Research Frederick Banting and Charles Best Doctoral Canada Graduate Scholarship (FRN 170883) and a University of Toronto Temerty Faculty
of Medicine Hold’em for Life Oncology Clinician Scientist Award.

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editors (Scott Swanson, Daniel Dolan) for the series “How to Evaluate, Diagnose and Treat Small Lung Nodules” published in Current Challenges in Thoracic Surgery. The article has undergone external peer review.

Reporting Checklist: The authors have completed the Narrative Review reporting checklist. Available at http://dx.doi.org/10.21037/ccts-20-122

Peer Review File: Available at http://dx.doi.org/10.21037/ccts-20-122

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/ccts-20-122). The series “How to Evaluate, Diagnose and Treat Small Lung Nodules” was commissioned by the editorial office without any funding or sponsorship. AG reports grants from the Canadian Institutes of Health Research, and grants from the University of Toronto Temerty Faculty of Medicine/Hold’em for Life Charity Challenge, during the conduct of the study. KY reports grants and personal fees from Olympus Corporation, personal fees from Intuitive Surgical, personal fees from Medtronic, grants and personal fees from Johnson & Johnson, other from Auris Heath Inc, other from Concordia Healthcare, and grants from Siemens, outside the submitted work. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

12. Ng CSH, Chu CM, Lo CK, et al. Hybrid operating

doi: 10.21037/ccts-20-122